• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » 20 life sciences, IT organizations invest in tranSMART Foundation

20 life sciences, IT organizations invest in tranSMART Foundation

January 15, 2015
CenterWatch Staff

The tranSMART Foundation, a nonprofit organization headquartered in Wakefield, Mass., providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, said 20 life sciences and technology organizations have made substantial commitments by joining its membership program.

Members not only become integral parts of the Foundation's community, they also provide the financial support necessary to sustain the organization and continually enhance the tranSMART open-source platform.

The benefits of membership include participation in sustaining the tranSMART open-source community, the opportunity to sit on the board of directors and membership on the 3C operating committees (Code, Content and Community). The work of the Foundation is directed by the board and carried out by the 3C committees, their component working groups and the foundation management team.

"Since launching the membership program one year ago, we have had tremendous support from pharmaceutical, biotech and technology companies, as well as academic institutions who have become engaged in our efforts," said Keith Elliston, Ph.D., tranSMART Foundation CEO. "These organizations realize the value that the tranSMART open-source platform can offer to the advancement of translational medicine research, and the role of the tranSMART Foundation in catalyzing this community. We appreciate the dedication and support of all of our members, who have helped us mobilize the community to produce two new versions of the platform over the past 18 months."

The tranSMART Foundation is launching a new membership campaign for 2015. It will encourage each of its current members to renew its memberships and will bring new members to the Foundation at both the gold and silver levels.

ConvergeHEALTH by Deloitte, Oracle, PerkinElmer, Pfizer, Roche, Sanofi and Takeda all have joined at the gold level, which includes a minimum investment of $100,000 per year to fund the foundation. Additionally, Johns Hopkins University and the University of Michigan have joined as academic gold members. At this level, these organizations can elect a representative from their company to the tranSMART board of directors and have a representative on all three of the foundation's 3C operating committees.

Silver-level members include ARLION, AssureRx, Cognizant, Institute for Systems Biology, One Mind, Saama Technologies and the Hyve. Each of the silver members makes a minimum investment of $5,000 to $20,000 to help fund operations. Silver members have the opportunity to submit a representative to a pool of candidates to be elected the foundation's board, and can nominate one individual to one of the foundation's 3C committees.

The Foundation also has an affiliate program, whose members provide sponsorship and support for its activities. Affiliate members include BT-GS, Elevada, Harvard University and Rancho Biosciences.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing